Resonant Clinical Solutions Enhances Innovative Therapy Capabilities Through Acquisition of Creapharm Bioservices

Expansion of Innovative Solutions in Clinical Research

Resonant Clinical Solutions, a leading global provider of clinical solutions for life sciences companies, recently announced its acquisition of Creapharm Bioservices, a company based in France specializing in clinical trial support and packaging services. This strategic move marks a significant enhancement in Resonant's capabilities, particularly within the realm of advanced therapies and cryogenic storage.

With this acquisition, Resonant expands its existing Biorepository services in Europe, a crucial step toward supporting increasingly complex clinical programs, including cell and gene therapies which demand specialized handling and storage solutions.

Creapharm Bioservices is renowned for providing cutting-edge biobank and cryogenic storage services for biotherapeutics and Advanced Therapy Medicinal Products (ATMPs). These include nitrogen vapor phase storage at temperatures as low as -196 °C, mechanical deep-freezing, and compliance with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) regulations. This acquisition comes in response to the growing demands of the industry, as clinical pipelines shift toward more specialized procedures. A recent study conducted by IQVIA revealed that non-small molecule products, including advanced therapies, accounted for 46% of new clinical trial starts in phases I–III in 2024, a notable increase from just 38% five years prior.

"The life sciences sector increasingly requires partners with the expertise, infrastructure, and global reach to support a larger portion of the clinical trial lifecycle," stated Christophe Berthoux, CEO of Resonant Clinical Solutions. He emphasized that Creapharm Bioservices enhances the company's capabilities to support clients developing complex and sensitive therapies, thereby amplifying Resonant's existing offerings in Biorepository, Kitting, and ancillary equipment. Together, these capabilities bolster the strategy to capture a more significant share of the clinical process on a global scale.

With this integration, Creapharm joins Resonant’s Biorepository segment, extending its global footprint and technical expertise in cryogenic storage and the handling of highly sensitive biological materials. This collaboration will introduce new services such as highly specialized cryogenic storage, tracking from controlled room temperature to cryogenic storage, and compliance with GMP and GDP requirements. Furthermore, Creapharm brings critical relationships and advanced technical know-how necessary for the management of sensitive materials.

"Creapharm Bioservices significantly strengthens the specialized support we can offer clients who work with highly sensitive materials and complex clinical programs," commented Corey Stone, VP and General Manager of the Biorepository sector at Resonant Clinical Solutions. "We are excited to welcome the Creapharm team and build upon their strong technical expertise and established customer relationships."

Greg Lavin, Chairman of Myonex, added, "Creapharm's specialized expertise aligns perfectly with Resonant's global Biorepository offerings. This transaction allows Myonex to further focus on our core competencies and future strategy, and we look forward to seeing the Creapharm team succeed under Resonant’s leadership."

While the financial details surrounding this acquisition remain undisclosed, the merger signifies a vital alignment of goals that promises to enhance the clinical trial landscape significantly.

Conclusion

Included in Resonant’s comprehensive services are solutions that are designed to navigate complex workflows, minimize risks, and propel vital clinical programs worldwide. With a workforce of over 850 employees spanning the USA, UK, and Europe, Resonant has successfully supported more than 2,500 clinical trials, facilitated over 20,000 deliveries to customer sites, and manages over 100 million research materials in storage. The company services a diverse portfolio including pharmaceutical and biotechnology firms, Contract Research Organizations (CROs), Contract Development and Manufacturing Organizations (CDMOs), and diagnostic and reference laboratories.

Resonant Clinical Solutions remains dedicated to delivering integrated global solutions for the clinical supply chain and sample lifecycle, removing complexities and allowing partners to focus on science and patients. For further information on their services and capabilities, visit resonantclinical.com.